Elevated levels of plasma homocysteine are associated with neurotoxicity

Atherosclerosis

Volumn 174, Issue 1, 2004, Pages 87-92

  Bisschops, Robertus H C ^a   Van Der Graaf, Yolanda ^a   Mali, Willem P Th M ^a   Van Der Grond, Jeroen ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular risk factors; Homocysteine; MR spectroscopy

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLINE; CREATINE; HOMOCYSTEINE; N ACETYLASPARTIC ACID;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN METABOLISM; CARDIOVASCULAR RISK; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; COMORBIDITY; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INCIDENCE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PROBABILITY; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 2342586554     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.01.005     Document Type: Article

References (16)

1. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057
2. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 277:1997;1775-1781
3. Stubbs P.J., Al Obaidi M.K., Conroy R.M., et al. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation. 102:2000;605-610
4. den Heijer T., Vermeer S.E., Clarke R., et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 126:2003;170-175
5. Vermeer S.E., van Dijk E.J., Koudstaal P.J., et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann. Neurol. 51:2002;285-289
6. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease. Lancet. 354:1999;407-413
7. Lipton S.A., Kim W.K., Choi Y.B., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5923-5928
8. Maheshwari S.R., Fatterpekar G.M., Castillo M., Mukherji S.K. Proton MR spectroscopy of the brain. Semin. Ultrasound CT MR. 21:2000;434-451
9. Simons P.C., Algra A., van de Laak M.F., Grobbee D.E., van der G.Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur. J. Epidemiol. 15:1999;773-781
10. Shipchandler M.T., Moore E.G. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin. Chem. 41:1995;991-994
11. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41
12. Ordidge RJ, Bendall MR, Gordon RE, Connelly A. Volume selection in vivo spectroscopy. In: Govil G, Khetrapal C, Saran A, editors. Magnetic resonance in biology and medicine. New Delhi, India: Tata McGraw-Hill; 1985. p. 387-97.
13. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann. N.Y. Acad. Sci. 508:1986;333-348
14. Kubo H., Harada M., Sakama M., Nishitani H. Reproducibility of metabolite concentration evaluated by intraclass correlation coefficient using clinical MR apparatus. J. Comput. Assist. Tomogr. 27:2003;449-453
15. Chard D.T., McLean M.A., Parker G.J., MacManus D.G., Miller D.H. Reproducibility of in vivo metabolite quantification with proton magnetic resonance spectroscopic imaging. J. Magn. Reson. Imaging. 15:2002;219-225
16. Engelbrecht V., Rassek M., Huismann J., Wendel U. MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. AJNR Am. J. Neuroradiol. 18:1997;536-539